Literature DB >> 9930658

Nitric oxide synthase expression in cervical spinal cord in sporadic amyotrophic lateral sclerosis.

N K Wong1, M J Strong.   

Abstract

Nitration of neurofilament (NF) has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Evidence of such includes elevated 3-nitrotyrosine levels in spinal cord tissue and localized nitrotyrosine immunoreactivity with neurofilamentous aggregates in cortical and spinal motor neurons. To determine if neuronal nitric oxide synthase (nNOS) and inducible NOS (iNOS) are the sources of nitric oxide in sporadic ALS (sALS), particularly through over-expression of the enzyme, steady-state mRNA levels of these isoforms were studied by in situ hybridization. Paraffin-embedded, archival cervical spinal cord tissues from 7 sALS and 6 control cases were used. 35S-labeled riboprobes were generated from partial cDNAs. Immunohistochemistry was utilized to confirm results of iNOS hybridization. We observed that nNOS mRNA was constitutively expressed in cervical spinal motor neurons. However, iNOS mRNA and iNOS immunoreactivity was not observed in ALS or control motor neurons. Our observations suggest that the source of nitric oxide is the endogenous nNOS. Together with the results from other immunohistochemical studies, we further hypothesize a possible role of translational deregulation of nNOS in sALS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9930658     DOI: 10.1016/S0171-9335(98)80092-7

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  2 in total

Review 1.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

2.  Specific electron transport chain abnormalities in amyotrophic lateral sclerosis.

Authors:  Jerry Lin; Andrew Diamanduros; Soheli A Chowdhury; Stephen Scelsa; Norman Latov; Saud A Sadiq
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.